Aytu BioPharma, Inc. (AYTU) investor relations documents from the company's IR site: 1 presentation; latest deck 2026-05-12. Read in-app with summaries. First-party data.
View Presentation: Aytu BioPharma is a CNS-focused pharmaceutical company whose primary growth driver is the recent launch of EXXUA, a novel, first-in-class MDD treatment.
| Published | Type | Document |
|---|---|---|
| 2026-05-12 | Presentation | View Presentation |
| 2024-10-09 | Regulatory report | Download PDF |
AYTU overview · AYTU earnings · AYTU financials · AYTU KPIs · AYTU ownership · AYTU peers · AYTU filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.